Expertise & Lab Services

Expertise & Lab Services

Our analytical expertise provides contract R&D solutions for industries where quality control and process optimization are critical to success.

When you get your start serving drug developers and pharmaceutical companies, quality and attention to detail become hardwired into your DNA. Today our FDA-inspected, ISO-accredited, and cGMP-compliant facilities are uniquely positioned to provide lab services across a diverse range of industries spanning criminal forensics applications to the healthcare, energy, transportation, and aerospace industries.

Let our carefully built team of experts show you why Gateway Analytical is your field’s partner of choice.

Expert cGMP testing services focused exclusively on parenteral product development, manufacturing, quality control testing, and regulatory support.

ISO & USP particle testing methods adapted for infusion and transfusion equipment for medical use, containers, & needle-based systems for intravenous injections.

We can assess functionality for intended use, extractables and leachables, and physical chemical compatibility. 

Get to know the experts and support staff that you’ll be working with. We’re all here to help.

Get one-on-one support from our individual team members. Learn more about their expertise — and what makes them truly unique people.

Emily Landsperger
Laboratory Manager

Dakotah Biler
Associate Scientist

Ashley Harrigan
Scientist I

Holly Hutchinson
Scientist I

Expert lab services

Crystal Lake, Illinois, June 10, 2019 – AptarGroup, Inc. today announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.

Nanopharm, located in Newport, UK, is a science-driven, leading provider of orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, PA, provides industry-leading particulate detection and predictive analytical services to customers developing injectable medicines. The companies’ results will be included in the Pharma segment and the transactions are not expected to be dilutive to Aptar’s earnings in 2019.

“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” commented Gael Touya, President of Aptar Pharma. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”

Stephan Tanda, President and CEO, stated, “These strategic investments further strengthen our best in class Pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings. The expertise of two established leaders, Nanopharm, a leader in inhalation and nasal drug development services, and Gateway, a leader in particulate detection and analysis for the injectables market, are complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”

Download the full press release